Well when events change, I change my mind. What do you do?
In many countries, reimbursement decisions are informed by estimates of the relative cost-effectiveness of alternative technologies, with costs and health outcomes projected over the lifetime of patients. Most cost-effectiveness analyses (CEAs) use decision models populated with evidence from randomized controlled trials (RCTs) that do not follow all patients until death. In the presence of such censored data, analyses of clinical effectiveness tend to use Cox proportional hazards regression models and avoid specifying a baseline hazard. This approach is insufficient for CEA, which must predict expected survival over time, a process that often requires extrapolation beyond the RCT follow-up data.
There are many options for conducting such extrapolations and great uncertainty as to the best choice of approach; consequently, gaming by manufacturers is a potential concern. A standard approach is to apply parametric survival functions to the individual patient data (IPD) from RCTs to predict mean survival by treatment arm, over the lifetime. Davies and others 1 illustrate just how important and uncertain model selection for extrapolation can be, even in the simple setting where IPD are available to estimate relative effectiveness for the 2 comparators of interest. Davies and others updated a CEA of 2 alternative prostheses for total hip replacement using 16 years of follow-up data, rather than the 8 years that were available at the time the previous study was conducted, and found that the original conclusion was overturned. How critical should we be of the previous CEAs, which may have provided the best recommendation given the evidence available at that time? Who is to say that the current results, which still do not follow all patients for their lifetime, represent the truth?
Rational decision making requires extrapolation approaches that are grounded in objective criteria and make efficient use of all evidence available at the time of decision. Recent reviews of technology appraisals for the National Institute for Health and Care Excellence (NICE) have shown that studies used extrapolation approaches that were inadequate or inadequately described.
2-4 Latimer's paper, 2 which summarizes a longer report, 3 proposes an algorithm to help future analysts improve their approach to extrapolation. The algorithm is limited to CEAs that compare 2 alternatives in which IPD are available from the pivotal RCT and there is no treatment switching. Within this context, there are 3 main suggestions: first, select the range of candidate models from a description of the occurrence of events over time, specifically by plotting the log of the cumulative hazards against the log of time; second, fit the chosen range of models to the entire RCT dataset and assess their relative fit to the observed data; and third, consider the relative plausibility of the predictions in the unobserved period. The development of the algorithm is to be welcomed, given the current state of both applied and methodological work in this area. We believe that the algorithm can improve the accuracy of extrapolations that are undertaken, not least by encouraging analysts to report a broader range of approaches than is current practice (in effect, report a structural sensitivity analysis). That said, we think further consideration of the 3 main suggestions is required, and we wish to encourage broader debate.
The algorithm suggests that analysts should pursue only flexible extrapolation approaches, such as spline-based models, 5 if simpler parametric models appear ''unsuitable.'' While we are sympathetic to the principle, our concern is the recommendation that suitability is judged solely from log-log plots. This criterion relies on a visual comparison of curves that ignores uncertainty. Moreover, the log time scale compresses the data from the later years of follow-up, which are most informative for the extrapolation, into a narrow portion of the plot on the right-hand side. Hence, these log-log plots make the more important section of the data visually less important, and so they may be given less weight than they deserve.
There are other useful assessments that should be considered before restricting model choice, including a priori reasoning for the relationship between mortality and follow-up time (for instance, from previous literature or biological rationale) and plots of hazard against follow-up time or age.
6 If Latimer's proposed algorithm is extended to broader criteria, this will encourage analysts to consider a wider range of models, including, for example, piecewise splines, mixture models, or fractional polynominals. 5, 7 Further research is required into the relative merits of these more flexible alternatives for the specific purpose of extrapolation. In the meantime, setting a wider scope for sensitivity analysis around extrapolated health outcomes will better inform decision makers about the uncertainty surrounding these estimates.
When one is choosing survival models, goodness of fit to the observed data is obviously an important criterion. We agree with Latimer that there is no guarantee that the parametric function that best fits the observed data will give accurate predictions in the unobserved period. The data sampled in a single RCT are often noisy, and we must consider external information to try to reduce uncertainty in the extrapolation. Hence, we must be careful that the algorithm's emphasis on assessing the fit of a limited set of parametric models to the entire RCT dataset does not deter analysts from considering useful alternatives. We acknowledge that encouraging analysts to fit parametric survival functions to the entire sample may be seen as less arbitrary than selecting portions of the observed data for model fitting. However, in many CEAs, for example, for interventions initiated in acute care, mortality is unusually high in the period immediately after randomization, and fitting survival functions to later sections of the RCT data may provide more accurate projections beyond the study period. We propose that a more general principle would be for CEAs to state in advance that extrapolation would be based on the section of the curve judged most representative of long-term survival, and to reduce scope for gaming this would have to be carefully justified with reference to external data (see below).
We agree that when one is choosing the model for extrapolation, the key criterion is the plausibility of long-term predictions, but Latimer's algorithm does not say how plausibility is to be evaluated, reflecting the lack of guidance available from the methodological literature. Would asking a few friendly clinicians to designate their pet extrapolations be deemed sufficient? The recent investments in comparative effectiveness research have encouraged development of large observational databases and registries that can track patients' prognosis over time. This provides opportunities for analysts to assess the accuracy of long-term predictions from the RCT data, at least for the usual care arm. A simple way to use such external data is to exclude, or downweight, those survival functions that do not accurately predict long-term survival in the external data. For example, for patients surviving an intensive care admission, survival functions that predict lower long-term mortality than for the age-and gender-matched general population may be judged implausible. Responsible use of external longitudinal data, however, raises further questions. For example, how should the analysis accommodate changes in clinical practice over time, acknowledge differences in unobserved characteristics between the routine and RCT settings, and recalibrate the RCT data to the characteristics of the general population? Ongoing research is addressing some of these issues, for example, in considering external data as constraints when specifying survival functions (Guyot and others, personal communication) .
While external data may improve predictions of the prognosis for patients receiving usual care, there may be little information for the new technology on outcomes beyond those observed in the RCTs. An outstanding problem is therefore what to assume about the relative treatment effect in the unobserved period, and Latimer's algorithm offers minimal guidance on this issue. This assumption should be assessed carefully and the results reported as part of a full assessment of structural uncertainty. The 2013 NICE technology appraisals guide 8 requests that submissions report scenarios with the following alternative assumptions about the treatment effect in the unobserved period: no treatment effect in the unobserved period, a treatment effect that declines over time, and a continuation of the main treatment effect reported from the RCT. A further scenario to consider is to predict treatment effects over time in the unobserved period, using information on timevarying treatment effects estimated from the RCT. While protagonists of model averaging might suggest that these alternative scenarios could be weighted, for example, by expert opinion about their relative probabilities, 9 perhaps it would be more helpful to avoid compressing the structural uncertainty in this way. Regardless of model choice, the assumed relative treatment effect over time, particularly post trial, must be reported.
Future decision making would be aided by methodological research to assess the relative merits of alternative model choices for extrapolation, specifically around the pros and cons of more flexible approaches to specifying survival functions and how best to incorporate external data. Such research should extend to common settings in which evidence on relative effectiveness comes from network metaanalyses 4 and treatment switching occurs, for instance, after disease progression. 10 Statistical wizardry cannot, however, compensate for poorly designed CEAs, and here decision-making agencies have an important role to play. The size of the extrapolation problem could be much reduced by encouraging manufacturers to submit CEAs with the most mature survival data available. To encourage greater objectivity in the choice of extrapolation approach, manufacturers should be required to make IPD data available to decision-making agencies. This would facilitate independent analyses that can assess the relative accuracy of alternative extrapolation approaches, as judged against external data; fully report structural uncertainty, for example, according to duration of assumed treatment effects; and report estimates of effectiveness and cost-effectiveness of a full range of treatment alternatives.
In conclusion, the recent articles by Davies and others and by Latimer represent an alarm call for any who feel that CEA methods are routine and can be put into a simple algorithm. It is inevitable that decisions will be made that, with hindsight, should be reversed. The processes followed by decision-making agencies allow, at least in theory, previous decision analyses to be updated with more mature survival data. In reality, though, the dissemination of the technology may be irreversible, and so there is an urgent need for analysts to improve the approaches they take to extrapolation by making full use of data beyond those available from RCTs.
